QX008N (Joincare R&D code: JKN2401) is a humanized IgG1 monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), being developed for the treatment of moderate-to-severe asthma and moderate-to-severe chronic obstructive pulmonary disease (COPD). Represented by Tezspire® (tezepelumab), TSLP-targeted therapy is currently the only globally approved biologic treatment for all phenotypes of asthma. This class of therapy does not require prior testing for specific biomarkers such as blood eosinophil count or IgE levels, and has been shown to significantly reduce the risk of asthma exacerbations and delay disease progression, regardless of the patient’s baseline eosinophil count or allergic status.

    In January 2024, Qyuns entered into a license-out agreement with Joincare, granting the latter exclusive rights to develop, manufacture, and commercialize QX008N in mainland China, the Hong Kong SAR, and the Macao SAR. As of April 2026, Joincare has initiated a Phase III clinical trial in China evaluating QX008N for the treatment of chronic obstructive pulmonary disease (COPD), making it the fifth product in the pipeline of Qyuns to enter Phase III clinical stage.